Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAESTRA 1: INCB123667 in platinum-resistant ovarian cancer with cyclin E1 overexpression
2025-521513-14-00Phase 2Authorised
- Sponsor
- Incyte
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of INCB123667 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Incyte. Primary endpoint: Objective response rate by independent review committee. Planned start Feb 2026; status: authorised.
02
Drugs
INCB123667
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2025-521513-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521513-14-00.